Course of Care of a Multiple Sclerosis Patient in the Context of Pharmacotherapy
DOI:
https://doi.org/10.15225/PNN.2015.4.3.6Keywords
multiple sclerosis, immunomodulatory therapy, monoclonal antibodiesAbstract
Multiple sclerosis (SM) is an incurable, advancing, demyelinating illness with inflammatory background. It constitutes the most frequent cause of disability among young people, between 20 and 40 years of age. Despite the identification of multiple factors causing the disease, its pathomechanism has not been yet completely discovered. For this reason, finding an effective cure for multiple sclerosis continues to present a challenge (for modern scientists). The currently available treatment for SM aims to halt its progress and to minimalize complications related to the disease. The goal of the work was to provide an overview of the therapies currently available to those suffering from SM. Selecting an appropriate form of treatment and medication as well as preparing the patient and continuation of monitoring during the therapy constitute important elements of conducting an effective SM therapy.
(JNNN 2015;4(3):130–137)
References
Selmaj K. Modele doświadczalne chorób autoimmunologicznych. W: Losy J., Selmaj K. (Red.), Neuroimmunologia kliniczna. Wydawnictwo Czelej, Lublin 2007;31–48.
Lassman H.,van Horssen J. The molecular basis of neurodegeneration in multiple sclerosis. FEBS Lett.
;585:3715–3723.
Selmaj K., Losy J., Neuroimmunologia kliniczna. Czelej, Lublin 2007.
Selmaj K. Rehabilitacja. W: Selmaj K. (Red.), Stwardnienie rozsiane. Termedia Wydawnictwo Medyczne, Poznań 2006:271–276.
Ropper A.H., Samuels M.A. Multiple Sclerosis and Demielinating Diseases. Adams and Victor Principles of Neurology. 9 edition Mc Graw Hill 2009.
Sawcer S., Jones H.B., Feakes R. et al. A genome screen in ultiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat Genet. 1996;13:464–468.
Simson S., Blizzard L., Otahal P., Van der Mei I., Taylor B. Latitude is significantly associated with the prevelance of multiple sclerosis; a met-analysis. Journal of Neurology, Neurosurgery and Psychiatry.
;82(10):132–1141.
Lonergan R., Kinsella K., Fitzpatric P. et al. Multiple Sclerosis prevelance in Ireland:relationship to vitamin D status and HLA genotype. Journal of Neurology, Neurosurgery and Psychiatry. 2001;82(3):317–322.
Łobińska A., Stemasiak Z. Epidemilogical aspects of multiple sclerosis in Lublin (Poland). NeurolNeurochir Pol. 2004;38:361–366.
Potemkowski A. Stwardnienie rozsiane w Polsce i na świecie. Aktualności neurologiczne. 2009;9:91–98.
Selmaj K. Naturalny przebieg SM. Stwardnienie rozsiane. Termedia Wydawnictwo Medyczne, Poznań
Wender M., Liberski P. Neuropatologia. W: Losy J. (Red.), Stwardnienie rozsiane. Wydawnictwo Czelej,
Lublin 2013;41–42.
Hauser S. Goodin D. Stwardnienie rozsiane i inne choroby demielinizacyjne. W: Harrison. Neurologia
w medycynie klinicznej. Wydawnictwo Czelej, Lublin 2008;479–500.
Bonek R., Maciejek Z. Naturalny przebieg stwardnienia rozsianego. Aktualn Neurol. 2009;9(2):116–
McDonald W.I., Compston A., Edan G. et al. Recommended diagnosticcriteria for multiple
sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol.
;50:121–127.
Visser L.H., Soelberg Sorensen P. Ostrerzutystwardnieniarozsianego. W: Hughes R., Brainin
M., Gilhus N.E. (Red.), Zasady postępowania w neurologii. Zalecenia EFNS, tom I. ViaMedica
;157–167.
Selmaj K. Leczenie objawowe. Stwardnienie rozsiane. Termedia Wydawnictwo Medyczne, Poznań
;257–270.
Kozibutowska Z. Diagnostyka, rokowanie i leczenie w stwardnieniu rozsianym w kontekście zagadnień
rehabilitacji. Polski Przegląd Neurologiczny. 2008;4(supl. A):46–47.
Wilkiewicz M., Jaracz K. Stwardnienie rozsiane. W: Jaracz K., Kozubski W. Pielęgniarstwo neurologiczne.
PZWL, Warszawa 2008;257–264.
Podlecka-Piętowska A. Leczenie modyfikujące przebieg choroby w stwardnieniu rozsianym. Neurologia
po dyplomie. 2008;3(5):11–18.
Selmaj K. Leczenie immunomodulacyjne. Stwardnienie rozsiane. Termedia Wydawnictwo Medyczne,
Poznań 2006;217–223.
The IFNB MutipleScleosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple
sclerosis. Clinical results of multicenter randomized, double-blind, placebo-controlled trial. The
IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4):655–661.
Kappos L., Freedman M.S., Polman C.H., Edan G., Hartung H.P., et al., BENEFIT Studz Group
Long+term effect of earlz treatment with interferon beta-1b after first clinical event suggestive of
multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol.
;8(11):987–997.
PRISM Group. Randomised double-blind placebo-controlled study of interferon b- 1a inrelapsing/
remitting multiple sclerosis. Ann Neurol. 1996;39:285–294.
Filippi M., Rovaris M., Inglese M. et al. Interferon beta-1a for brain tissue loss in patients at presentation
with syndromes suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled
trial. Lancet. 2004;364(9444):1489–1496.
O’Connor P., CHAPMS: The effects of intramuscular interferon beta-1a in patients at high risk for development
of multiple sclerosis: a post hoc analysis of data from CHAPS. ClinTher. 2003;25(11):2865–2874.
Shirani A., Zhao Y., Karim M.E. et al. Association between use of interferon beta and progression of
disability n patients with relapsing-remitting multiple sclerosis. JAMA. 2012;308(3):247–256.
Comi G., Filipi M., Wolinsky J.S. European/Canadian Glatiramer Acetate Study Group. European/
Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatirameru
acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing
multiple sclerosis. Ann Neurol. 2001;49(3):290–297.
Terapeutyczne Programy Zdrowotne 2012, Stwardnienie Rozsiane, załącznik nr 15 do zarządzenia nr
/2011DGL Prezesa NFZ, załącznik nr 6;1–8.
Wilkiewicz M. Diagnoza pielęgniarska i plan opieki nad chorym ze stwardnieniem rozsianym. W: Jaracz
K., Kozubski W. (Red.), Pielęgniarstwo neurologiczne. PZWL, Warszawa 2008;257–264.
Wilkiewicz M., Smelkowska A., Jaracz K., Grabowska-Fudala B., Pniewska J. Opieka pielęgniarska nad
pacjentem ze stwardnieniem rozsianym w trakcie leczenia immunomodulacyjnego lekami pierwszego
rzutu. Pielęgniarstwo Neurologiczne i Neurochirurgiczne. 2013;2(5):223–227.
Johnson K.P., Brooks B.R., Cohen J.A. et al. Extended use of glatirameru acetate (Copaxone) is
well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability.
Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1998;50(3):701–708.
Nursing management of the patients with multiple sclerosis. AAN, ARN and IOMSAL clinical practice
qudeline series. TEVA neuroscience. 2011;38–41.
Buhse M. Assessment of caregiver burden in families of persons with multiple sclerosis. The Journal of
Neuroscience Nursing. 2008;40(1):25–31.
Corry M. & While A. The needs of carers of people with multiple sclerosis: A literature review. Scandavian
Journal of Caring Sciences. 2008;23(3):569–588.
Food and Drug Administration News Release (2010) http://www.fda.gov/NewsEvents/Newsroom/
PressAnnouncements/2006/ucm 108662. htm.
Polman C.H., O’Connor P.W., Havrdova E.A randomized, placebo-controlled trial of natalizumab
for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910.
Langer-Gould A., Atlas S.W., Green A. Progressive multifocal leukoencephalopathy in a patient treated
with natalizumab. N Engl J Med. 2005;353:375–381.
Van Assche G., Van Ranst M., Sciot R. Progressive multifocal leukoencephalopathy after natalizumab
therapy for Crohn’s disease. N Engl J Med. 2005;353:362–368.
Załącznik do obwieszczenia ministra zdrowia z dnia 26 października 2012 roku, leczenie stwardnienia
rozsianego po niepowodzeniu terapii lekami pierwszego rzutu lub szybko rozwijającej się klinicznie
postaci stwardnienia rozsianego (ICD-10 G35); 1–9.
Kappos L. et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient
selection and monitoring. Lancet Neurol. 2011;10(8):745–758.
http://www.ema.europa.eu/docs/pl_PL/document_library/EPAR_-_Product_Information/human/
/WC500044686.pdf
Chun J., Hartung H.P. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin-
Neuropharmacol. 2010;33:91–101.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Stats
Number of views and downloads: 46
Number of citations: 0